Press resources.
For reporters covering peptide science, GLP-1s, FDA regulatory action, or compounding pharmacy. Feel free to use any of the below with attribution. We're happy to source-check your draft, provide original data from our coverage, or be quoted.
About The Peptide Examiner
The Peptide Examiner is an independent editorial publication covering peptide science, GLP-1 receptor agonists, longevity research, and FDA regulatory action. Newsletter-first. Not a vendor. Not a clinic. Not a dosing guide.
- Founded: April 2026
- Canonical URL: thepeptideexaminer.com
- Coverage: 20 peptide evidence pillars, 22 head-to-head drug comparisons, live FDA regulatory tracker, clinical-trial readout calendar, weekly news desk.
- Editorial standards: Read our editorial policy — sourcing hierarchy, evidence tiers, AI-drafting rules, corrections process.
- Funding: Reader-supported newsletter + disclosed affiliate relationships with FDA-approved telehealth providers and vetted compounding pharmacies. We do not accept vendor sponsorship of content.
Contact
- Press / media: press@thepeptideexaminer.com — typical response within 24 hours on weekdays.
- Tips / story leads: tips@thepeptideexaminer.com — we protect sources.
- Corrections: corrections@thepeptideexaminer.com
For expert comment on specific stories, see our expert-source page.
Editorial stance worth citing
- No dosing content, no “where to buy” articles for research peptides. Every peptide page flags this explicitly.
- Affiliate-only vendor display. Vendors without an active affiliate relationship with us don't appear on the site as commercial recommendations (though they may appear in editorial analysis like our Vendor Transparency Index).
- Evidence tiers labeled on every peptide page: well-established, moderate human data, limited human data, preclinical/animal-only.
- Primary-source citations in first 300 words of every evidence pillar.
Quotable data
Cite with attribution and link back. All figures are independently verifiable from the primary sources we cite.
Estimated number of patients affected when compounded semaglutide discretion ended in April-May 2025.
Source: Per our analysis; see /news/compounded-semaglutide-april-2026
Mean weight loss at 72 weeks for tirzepatide 15 mg vs semaglutide 2.4 mg in the SURMOUNT-5 head-to-head trial.
Source: NEJM 2025
Peptides HHS proposed removing from FDA Category 2 in February 2026; includes BPC-157, GHK-Cu, CJC-1295, MOTS-c, thymosin-alpha-1.
Source: Our FDA tracker at /fda
LillyDirect Self Pay price range for Zepbound vial (tirzepatide) for uninsured or under-insured patients, 2026.
Approximate fraction of weight lost on GLP-1 receptor agonists that comes from lean mass rather than fat mass.
Source: Per GLP-1 body-composition substudies; see /news/muscle-loss-glp1-2025-evidence-reviewed
Major research-peptide vendors in our Vendor Transparency Index with an active affiliate relationship to The Peptide Examiner. We publish editorial scoring independent of monetization.
Source: Vendor Transparency Index v1
High-interest coverage to link or cite
- FDA peptide tracker — live regulatory status across 20 peptides.
- FDA enforcement timeline 2023–2026 — Category 2 listings, shortage cutoffs, warning letters.
- Vendor Transparency Index v1 — editorial scoring of 10 peptide vendors.
- Trial readout calendar — upcoming Phase 3 readouts and regulatory decisions.
- HHS proposes removing 14 peptides from Category 2 — the politics and what happens next.
- Compounded semaglutide is gone — what patients should know.
Machine-readable data
- /data/peptides.json — full peptide registry with status, category, canonical URLs
- /feed.xml — RSS feed (peptides, comparisons, news)
- /llms.txt — LLM crawler guidance
Embargoed reports
Quarterly “State of Peptide Regulation” reports go under embargo to a short list of journalists 72 hours before public release. To request embargo access, email press@thepeptideexaminer.com with your outlet and coverage beat.